André Choulika, PhD
Chairman of the Board of Directors and CEO
André Choulika, Ph.D., is one of the founders of Cellectis and served as Chief Executive Officer since the company's inception in 1999. He is Chairman of the Board of Directors since 2011 and President of Calyxt since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +). In June 2019, Dr. Choulika was appointed to the Board of Directors of the Institut Pasteur.
Carrie Brownstein, MD
Chief Medical Officer
Dr. Carrie Brownstein joined Cellectis in April 2020 as Chief Medical Officer, where she oversees clinical research and development and is responsible for the strategy and tactical implementation of Cellectis’ clinical stage programs from candidate selection through commercialization. Dr. Brownstein joined Cellectis as a seasoned clinical and medical expert from Celgene, where she most recently served as Vice President, Global Clinical Research and Development, Therapeutic Area Head for myeloid diseases, managing a clinical team of physicians and scientists across multiple global sites. Prior to Celgene, Dr. Brownstein served as Executive Director, Clinical Sciences Oncology at Regeneron Pharmaceuticals where she led teams investigating multiple early development programs and assets, including T-cell engaging bispecific antibodies. Dr. Brownstein started her industry career at Hoffman-La Roche (Roche Pharmaceuticals), where she held roles of increasing responsibility, and most recently served as Senior Medical Director supporting the development and approval of hematology and oncology therapies.
Prior to her industry career, Dr. Brownstein practiced medicine as a Pediatric Hematologist/Oncologist on faculty at notable New York institutions including New York Presbyterian Columbia University and Mount Sinai Medical Center. Dr. Brownstein received her M.D. from Tufts University School of Medicine and completed her internship and residency at the Babies and Children’s Hospital of Columbia Presbyterian Medical Center (NYP, Morgan Stanley Children’s Hospital) in New York, NY, and completed her fellowship in Pediatric Hematology and Oncology at Memorial Sloan Kettering Cancer Center in New York, NY.
Philippe Duchateau, PhD
Chief Scientific Officer
Philippe Duchateau, Ph.D., joined Cellectis in 2001 to pioneer the field of gene editing and has served as Chief Scientific Officer since 2012. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur (Lille, France), he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco, within the Cardiovascular Research Institute. Dr. Duchateau has led Cellectis’ Research department since 2004.
Chief Financial Officer
Eric Dutang, Certified Public Accountant in France, joined Cellectis as Deputy Chief Financial Officer in May 2015. Eric began his career as financial auditor with KPMG, first in Paris for five years and then in New York for two years. He worked for publicly-traded companies in France and the U.S. including Vivendi, Veolia Environnement, and Cablevision. He then became a member of the transactions and advisory teams in Paris for seven years where he carried out acquisitions/disposals for both publicly-traded companies and private equity funds. After serving at KPMG, he worked on international business developments for French publicly-traded groups, including Air Liquide and Thales. Eric holds a Master of Finance and Executive MBA from HEC Paris (France)/Babson Massachusetts (USA).
Executive Vice President, Technical Operations
William (Bill) Monteith joined Cellectis in November 2018 as Senior Vice President US Manufacturing responsible for the selection, construction and buildout of Cellectis’ first gene-edited allogeneic manufacturing facility in the US called IMPACT. Bill Monteith was named Executive Vice President of Technical Operations in July 2019.
Before joining Cellectis, Mr. Monteith was the Chief Operating Officer for Hitachi Chemical Advanced Therapeutic Solutions (formerly PCT). While at Hitachi, He was part of the executive team overseeing the merger with Hitachi and went on to build a cell and gene therapy facility in Yokohama Japan in addition to being responsible for the US based facilities in Allendale New Jersey and Mountain View California. Prior to that, Mr. Monteith was the VP and General Manager, and then Executive VP, Technical Operations, for Dendreon which was the first autologous cellular therapy to get approval in the United States. He has also held leadership roles at Sandoz, Shire, and Wyeth pharmaceuticals, ranging from technical operations to quality assurance.
Bill Monteith is a dynamic global pharmaceutical Operations and Quality Executive with a documented record of organizational success and a proven record of accomplishment in strategic planning and execution, business process improvement, cost reduction, FDA and DEA regulatory compliance, facility startup and turnaround, technical transfer and analytical method validation, supply chain, and multi-plant management.
Mr. Monteith received his Bachelor of Science in pre-medical studies with a major in Chemistry from Saint Lawrence University in Canton, NY.
Chief Regulatory and Compliance Officer
Stephan Reynier, MSc, joined Cellectis in April 2011. He serves as Chief Regulatory and Compliance Officer after holding the position of Head of Programs at Ectycell, a former subsidiary of Cellectis, from April 2011 to 2014 with the mission of managing and coordinating internal and external collaborative programs. As Chief Regulatory and Compliance Officer, Mr. Reynier is in charge of ensuring a speedy and successful development of the UCART product family by establishing close interactions with regulatory agencies such as EMA and FDA, while securing compliance to applicable regulations, regulatory guidelines and quality assurance standards. Mr Reynier has extensive experience, from his previous positions as Senior Director at Voisin Consulting Life Sciences and European Associate Director Medical Affairs at Gilead Sciences, in the design and implementation of regulatory strategies for the development of drugs and biologics, with a strong focus on cell and gene therapy.
Mr Reynier graduated as Agro-Engineer in France and received a Master of Science in Chemical Engineering from the University of Toronto, Canada.
David Sourdive, PhD
Executive Vice President, Strategic Initiatives
David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016 and as Executive Vice President, Technical Operations until July, 2019. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.
Vice President, Corporate Development
Arthur Stril joined Cellectis in July 2018 as Vice President, Corporate Development and is responsible for program management, strategy and business development. Arthur began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers such as the Novartis/GSK and Sanofi/Boehringer Ingelheim asset swaps, Pfizer’s acquisition of Hospira and Teva’s acquisition of Actavis Generics. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the €80bn hospital budget. Arthur graduated from the École Normale Supérieure, Paris & Cambridge University, and holds a diploma in Immunotherapy from the Université Paris-Descartes. Arthur is also a member of the French Corps des Mines.
Marie-Bleuenn Terrier joined Cellectis as Legal Counsel in 2008, and was appointed General Counsel in 2013. Prior to joining Cellectis, she worked as Legal Counsel for Pfizer from 2004 to 2006, and for Boehringer Ingelheim from 2006 to 2008. Marie-Bleuenn Terrier has served as Secretary of the Board of Directors of Cellectis since 2015. She holds a Master’s degree in Law from the Panthéon La Sorbonne University in Paris.
Executive Vice President, Global Quality
Jon Voss joined Cellectis in July 2019 as Executive Vice President of Global Quality. Mr. Voss has over 30 years of US and international Quality expertise in gene therapy, small molecule, biologic and medical device products working as VP of Quality for such companies as Generation Bio, Sarepta Therapeutics and Genzyme. Having worked in early stage pre-clinical, clinical and commercial organizations, Mr. Voss has unique experience in moving companies from the development to commercial stage. As EVP of Global Quality, Mr. Voss is building the Cellectis global quality organization to support the existing Cellectis UCART clinical programs as well as ensuring that Cellectis is prepared for commercial licensure and the associated operations.
Mr. Voss earned his Bachelor of Science degree from the University of California at Davis and received his Master of Science in Biomedical Engineering from Boston University.
Laurent Arthaud has served as a member of Cellectis’ Board of Directors since 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement (formerly CDC Enterprises, a subsidiary of Caisse des Dépôts) since 2012. From 2006 to 2012, Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Mr. Arthaud is a graduate of the École Polytechnique and the l’École Nationale de Statistique et d’Administration Économique.
* Independent Director according to Nasdaq rules
Pierre Bastid has served as a member of Cellectis’ Board of Directors since 2011. Mr. Bastid has 25 years experience in turning around, developing and running technology businesses in Asia, Europe and the U.S. In particular, he initiated and completed the most successful European management buy out of the last 15 years: he bought the Power Conversion Division of French Engineering Alstom for $100M in 2005 and sold it to General Electric in 2011 for $3B.
In addition to his involvement with Cellectis, Mr. Bastid is currently a large shareholder, serving on the Board for Pharnext (another very innovative biotech company), Hougou (his own investment company), ZAKA and GRID (his own Paris based and New-York based real estate companies), Shango (his own Private Equity company), EVOK (his own hotel group), Nepteam (a shipbuilding company). Mr. Bastid also advises a number of Investment and Private Equity firms. Pierre is a trustee of Juilliard School of Music and other non-profit organizations based in the U.S.
*Independent Director according to Nasdaq rules
Rainer Boehm, MD
Rainer Boehm spent 29 years at Novartis, working locally, regionally and globally in various Senior Management roles, after building his career in Marketing & Sales and Medical Affairs. He led all emerging markets regions as well as the United States and Canada, either for Oncology or the Pharmaceuticals division. His most recent assignments were Chief Commercial and Medical Affairs Officer globally for Novartis Pharma, as well as ad interim CEO and Division Head Pharma. Rainer launched and oversaw the commercialization of many brands during his career, amongst them Femara, Zometa and Glivec, as well as Cosentyx and Entresto. His broad interests include leadership development, coaching and mentoring, access to medicines and new business models including solutions to leverage digital medicines and real world evidence. Rainer has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.
Mr. Godard has served as a member of Cellectis’ Board of Directors since 2007. He is a graduate of the Ecole Nationale Supérieure Agronomique de Toulouse and began his agronomy career in 1967 in Africa as a researcher at the Institut de Recherche pour les Huiles et Oléagineux. He joined the French chemical group Rhône-Poulenc in 1975 where he got various management positions in France and abroad before becoming CEO of the agrochemical subsidiary in 1991. In 1999 he was directly involved in the merger of Rhône-Poulenc and Hoechst to create Aventis and was appointed CEO of the Aventis CropScience subsidiary with a significant involvement in seeds and ag biotechnology. He left Aventis in 2002 to create a consulting company specialized in agriculture and biotechnology.
Hervé Hoppenot joined Incyte Corporation in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Incyte is one of the fastest growing biopharmaceutical companies in the U.S. Incyte’s team of more than 1,000 scientists, clinicians, and other team members operating in 15 countries, strives to discover and develop first-in-class and best-in-class medicines for cancer and other diseases. The Company is advancing a diverse portfolio of large and small molecules comprised of 18 development candidates against 14 different molecular targets and in 2016 Incyte reported revenue of more than $1 billion.
Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, which included $11 billion in global sales, the largest oncology pipeline in the industry and 8000 employees in 50 countries. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. He and his family are dual citizens of France and the United States, having moved to the U.S. in 1991.
Annick Schwebig, MD
Annick Schwebig, MD, has served as a member of Cellectis’ Board of Directors since 2011. In 2000, she founded the French subsidiary of Actelion, of which she is the General Manager. Actelion is a biopharmaceuticals company specializing in innovative treatments to serve unmet medical needs. A graduate of the University of Paris medical school, Dr. Schwebig worked as a senior manager at the biopharmaceuticals company Bristol-Myers Squibb for 17 years from 1983 to 2000.
Prof. Catherine Bollard
Director, Center for Cancer and Immunology Research, Children’s Research Institute, Children's National Health System and Professor of Pediatrics and Immunology, The George Washington University, Washington DC
Professor Catherine Bollard, MBChB, MD, FRACP, FRCPA, is Director of the Center for Cancer and Immunology Research and Director of the Program for Cell Enhancements and Technologies for Immunotherapy at the Children’s Research Institute, Children’s National Health System and The George Washington University. A distinguished hematologist and immunotherapist, Dr. Bollard’s research interests focus on areas that include developing cell and gene therapies for patients with cancer and underlying immune deficiencies.
Dr. Stephan Grupp
Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia
Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia (CHOP), and the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania. A bone marrow transplant physician, he is a member of the Division of Oncology and the Medical Director of the Cell and Gene Therapy Lab. Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date, as well as the global registration trial for CTL019. As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 180 peer-reviewed journal articles, as well as numerous abstracts and book chapters.
Prof. Ola Landgren
Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, New York, NY
Professor Ola Landgren, MD, is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center New York and Professor of Medicine at Weill Cornell Medical College. He is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring. He has a strong interest in the development of early-treatment clinical trials, targeting high-risk smoldering myeloma. He develops new strategies (including cell-based, molecular-based and imaging-based) and implements advanced MRD testing in clinical trials at MSK.
Dr. Marcela Maus
Director of Cellular Immunotherapy at the Massachusetts General Hospital, Boston, MA
Doctor Marcela V. Maus, MD, PhD, is Director of Cellular Immunotherapy at the Massachusetts General Hospital in Boston and Assistant Professor at Harvard Medical School. She is a board-certified hematologist-oncologist with extensive research experience in all aspects of pre-clinical and clinical design and use of cell therapies and gene-modified T-cells for cancer. Dr Maus completed undergraduate studies at MIT and her MD and PhD at Penn. As a graduate student, she worked with Dr. Carl June on the biology of human T cell activation. She completed residency training in internal medicine at the University of Pennsylvania Health System, and completed fellowship training in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center. Her research focuses on the pre-clinical development and clinical translation of engineered T cell therapies.
Prof. Ghulam J. Mufti
Professor of Hemato-oncology and Head of Department, King's College Hospital, Department of Hematological Medicine, London, UK
Professor Ghulam J Mufti is one of the founding members of The MDS Foundation Inc. He is also the head of the department of hematological medicine at Guy’s, King’s and St Thomas’s hospitals, King’s College London, with a team of 13 professors, 6 senior lecturers/lecturers and approximately 100+ research staff. In addition, Professor Mufti is a non-executive director of King’s College Hospital NHS Foundation Trust and was awarded an Officer of the Order of British Empire (OBE) in the Queen’s New Year honors list in January 2017.
Professor Ghulam Mufti has extensive clinical and research expertise in leukemias, lymphomas and in particular myelodysplastic syndromes, for which he is internationally renowned. His particular area of research has focused on molecular aberrations in MDS/AML and the identification of novel therapies that include gene and cell based therapies. He has published 500+ papers (H-Index: 78, I-Index: 11) and chapters in scientific journals and textbooks on leukemias /MDS and bone marrow failure syndromes.
Prof. Dietger Niederwieser
Professor of Medicine, Head of the Division of Hematology and Medical Oncology at the University of Leipzig, Germany
Professor Dietger Niederwieser, MD, is Professor of Medicine, Head of the Division of Hematology and Medical Oncology at University of Leipzig and University Hospital. His therapeutic areas of expertise include Clinical Immunology, Hematology and Oncology, and his research is focused on stem cell transplantation, cell therapies and gene therapies. He has extensive experience in health economics, outcomes research, clinical development of innovative drugs and clinical studies.
Prof. Kanti Rai
Professor of Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, USA
Professor Rai, an internationally renowned leukemia researcher and hematologist, brings extensive knowledge and experience from his 50-year career spanning groundbreaking clinical leukemia research. He is the Joel Finkelstein Cancer Foundation Professor of Medicine at the Hofstra North Shore-LIJ School of Medicine, where he is also Professor of Molecular Medicine. He is currently Chief of the Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program at Northwell Cancer Institute and an Investigator at The Feinstein Institute for Medical Research.